These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
620 related articles for article (PubMed ID: 21926377)
1. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT. Ohno Y; Koyama H; Yoshikawa T; Nishio M; Aoyama N; Onishi Y; Takenaka D; Matsumoto S; Maniwa Y; Nishio W; Nishimura Y; Itoh T; Sugimura K Radiology; 2011 Nov; 261(2):605-15. PubMed ID: 21926377 [TBL] [Abstract][Full Text] [Related]
2. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients. Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365 [TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer patients. Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Kassai Y; Yui M; Matsumoto S; Sugimura K Eur J Radiol; 2015 Nov; 84(11):2321-31. PubMed ID: 26231045 [TBL] [Abstract][Full Text] [Related]
4. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889 [TBL] [Abstract][Full Text] [Related]
5. Computed DWI MRI Results in Superior Capability for N-Stage Assessment of Non-Small Cell Lung Cancer Than That of Actual DWI, STIR Imaging, and FDG-PET/CT. Ohno Y; Yui M; Takenaka D; Yoshikawa T; Koyama H; Kassai Y; Yamamoto K; Oshima Y; Hamabuchi N; Hanamatsu S; Obama Y; Ueda T; Ikeda H; Hattori H; Murayama K; Toyama H J Magn Reson Imaging; 2023 Jan; 57(1):259-272. PubMed ID: 35753082 [TBL] [Abstract][Full Text] [Related]
6. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481 [TBL] [Abstract][Full Text] [Related]
7. The effectiveness of 18F-FDG PET/CT combined with STIR MRI for diagnosing nodal involvement in the thorax. Morikawa M; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Tsuchida T; Kimura H; Fujibayashi Y; Okazawa H J Nucl Med; 2009 Jan; 50(1):81-7. PubMed ID: 19091887 [TBL] [Abstract][Full Text] [Related]
8. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography. Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365 [TBL] [Abstract][Full Text] [Related]
9. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative assessment with diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient. Nakayama J; Miyasaka K; Omatsu T; Onodera Y; Terae S; Matsuno Y; Cho Y; Hida Y; Kaga K; Shirato H J Comput Assist Tomogr; 2010 Jan; 34(1):1-8. PubMed ID: 20118713 [TBL] [Abstract][Full Text] [Related]
10. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Ohno Y; Hatabu H; Takenaka D; Higashino T; Watanabe H; Ohbayashi C; Yoshimura M; Satouchi M; Nishimura Y; Sugimura K Radiology; 2004 Jun; 231(3):872-9. PubMed ID: 15163823 [TBL] [Abstract][Full Text] [Related]
11. Three-way Comparison of Whole-Body MR, Coregistered Whole-Body FDG PET/MR, and Integrated Whole-Body FDG PET/CT Imaging: TNM and Stage Assessment Capability for Non-Small Cell Lung Cancer Patients. Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Seki S; Yui M; Yamagata H; Aoyagi K; Matsumoto S; Sugimura K Radiology; 2015 Jun; 275(3):849-61. PubMed ID: 25584709 [TBL] [Abstract][Full Text] [Related]
13. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984 [TBL] [Abstract][Full Text] [Related]
14. Non-small cell carcinoma: comparison of postoperative intra- and extrathoracic recurrence assessment capability of qualitatively and/or quantitatively assessed FDG-PET/CT and standard radiological examinations. Onishi Y; Ohno Y; Koyama H; Nogami M; Takenaka D; Matsumoto K; Yoshikawa T; Matsumoto S; Maniwa Y; Nishimura Y; Sugimura K Eur J Radiol; 2011 Sep; 79(3):473-9. PubMed ID: 20547021 [TBL] [Abstract][Full Text] [Related]
15. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Yi CA; Shin KM; Lee KS; Kim BT; Kim H; Kwon OJ; Choi JY; Chung MJ Radiology; 2008 Aug; 248(2):632-42. PubMed ID: 18552311 [TBL] [Abstract][Full Text] [Related]
16. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054 [TBL] [Abstract][Full Text] [Related]
17. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high. Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432 [TBL] [Abstract][Full Text] [Related]
18. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging. Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400 [TBL] [Abstract][Full Text] [Related]
19. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results. Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802 [TBL] [Abstract][Full Text] [Related]
20. Increasing the accuracy of 18F-FDG PET/CT interpretation of "mildly positive" mediastinal nodes in the staging of non-small cell lung cancer. Moloney F; Ryan D; McCarthy L; McCarthy J; Burke L; Henry MT; Kennedy MP; Hinchion J; McSweeney S; Maher MM; O'Regan K Eur J Radiol; 2014 May; 83(5):843-7. PubMed ID: 24581594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]